You are here: Industry Insights > inhibitor

News List

Made-in-China New Drugs: Breaking Through the RMB 4-Billion Battlefield lezhi
September 05, 2025
In 2024, the "Billion-Yuan Club" of made-in-China first-in-class new drugs expanded to 16 members.
Has the Booming PD-1 Inhibitor Reached its Limit? Krebs Qin
October 18, 2024
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
Research Progress in Drug Therapy for Systemic Lupus Erythematosus Xiaonisha
September 03, 2025
Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by local or systemic inflammatory responses, with insidious onset and high potential morbidity and mortality rates.
Ubiquitin-Proteasome Pathway and Progress in Drug Development Xiaonisha
August 13, 2025
The ubiquitin-proteasome system serves as one of the crucial pathways for the "digestion" of intracellular proteins, regulating numerous vital biological processes such as cell proliferation, differentiation, apoptosis, and DNA repair.
Advances in the Research of Targeting B Cells for the Treatment of Systemic Lupus Erythematosus Xiaonisha
July 25, 2025
Systemic Lupus Erythematosus (SLE) is a chronic, systemic autoimmune disease. The direct cause of SLE pathogenesis lies in the immune imbalance resulting from excessive B-cell activation.
Can Myocarditis Lead to Heart Failure? Please Briefly Describe the Research Progress in Drug Treatment for Heart Failure Xiaomichong
July 23, 2025
Recently, there have been online rumors about some recovered COVID-19 "positive" patients who started intense exercise shortly after recovery and then suddenly died due to myocarditis.
Weekly Pharma News Review | PharmaSources.com (March 14 to 18) PharmaSources/Caicai
March 25, 2022
One of the most exciting news of this week was the marketing approval of duvelisib capsules, a dual PI3K inhibitor introduced by CSPC Pharmaceutical Group Co., Ltd.
NASDAQ Biopharma IPOs in the First Half of Q1 2022 David Orchard-Webb
March 01, 2022
So far in the first half of Q1 2022 seven biopharma companies have IPO’d on the NASDAQ.
Weekly Pharmaceutical News Review of PharmaSources.com (January 17th to 21st) PharmaSources/Caicai
January 25, 2022
The news review in this week is from January 17 to 21, covering a total of 19 pieces of information in 4 sections, i.e. review, transaction, R&D, and listing.
Weekly Pharma News Review of PharmaSources.com (January 10th to 14th) PharmaSources/Caicai
January 21, 2022
This week in review is the news from January 10-14, covering a total of 15 pieces of information in 3 sections, i.e. review, transaction, and R&D.

Previous page 1 2 3 4 5 Next page